Gliosarcoma is a rare, aggressive brain tumor classified by the World Health Organization (WHO) as a grade IV malignancy. It is a histological variant of glioblastoma — the most aggressive primary brain cancer — distinguished by a characteristic biphasic tissue pattern in which areas of glial (brain cell) differentiation alternate with areas of mesenchymal (connective tissue) differentiation. Gliosarcoma arises spontaneously from somatic mutations within brain cells and is not inherited; it does not run in families. It most commonly affects adults and behaves similarly to glioblastoma in terms of clinical course and treatment approach. This summary reflects clinical data available as of 2026-05-10.

Not all individuals experience all features, and severity varies considerably. Symptoms of gliosarcoma reflect the location and extent of the tumor within the brain. Common presentations include headaches, seizures, focal neurological deficits (such as weakness, speech difficulties, or vision changes), and cognitive or personality changes. As an aggressive, rapidly growing tumor, symptoms can develop and progress over weeks to months.

Gliosarcoma is an acquired condition arising from somatic (non-inherited) mutations that occur within brain cells during a person's lifetime. It is not caused by inherited genetic variants passed from parents to children, and having a family member with this tumor does not increase an individual's risk in the way that a hereditary condition would. The specific molecular events driving malignant transformation in gliosarcoma share features with glioblastoma, though the precise mechanisms underlying its distinctive biphasic histology remain an area of ongoing study.

Diagnosis is established by brain imaging — typically MRI — followed by surgical biopsy or resection with neuropathological examination. Histopathology demonstrating the characteristic biphasic glial and mesenchymal differentiation pattern is required to distinguish gliosarcoma from other high-grade gliomas. Molecular profiling of the tumor is increasingly performed to guide treatment decisions and prognosis.

Treatment of gliosarcoma follows approaches used for glioblastoma and typically includes maximal safe surgical resection, radiation therapy, and chemotherapy. Bevacizumab, an anti-angiogenic agent approved for use in malignant glioma, may be used in the management of recurrent disease. No therapy has been FDA-approved specifically for gliosarcoma as a distinct entity. Multiple clinical trials are actively enrolling patients with high-grade gliomas including gliosarcoma, evaluating immunotherapy, targeted agents, and combination approaches.

Gliosarcoma carries a poor prognosis, consistent with its WHO grade IV classification. Median survival with current standard-of-care treatment is generally measured in months to approximately one year, similar to glioblastoma. Outcomes vary based on tumor location, extent of surgical resection, and individual patient factors. Research into more effective therapies is ongoing.

Active clinical research is investigating new approaches for high-grade gliomas including gliosarcoma. Current studies include immune modulation with ultrasound for newly diagnosed glioblastoma (NCT05864534), combinations of chemotherapy agents, and imaging biomarker studies to better predict treatment response. Participation in clinical trials may provide access to investigational therapies and contributes to the advancement of treatment options for this rare tumor type.